

Title (en)  
METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS

Title (de)  
BEHANDLUNGSVERFAHREN MIT VERWENDUNG VON FETTSÄURESYNTHESEINHIBITOREN

Title (fr)  
PROCÉDÉ DE TRAITEMENT UTILISANT DES INHIBITEURS DE LA SYNTHÈSE D'ACIDES GRAS

Publication  
**EP 2946778 A1 20151125 (EN)**

Application  
**EP 15166422 A 20070918**

Priority  
• US 84646706 P 20060922  
• EP 13188869 A 20070918  
• EP 07838438 A 20070918

Abstract (en)  
The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat or prevent dyslipidemias.

IPC 8 full level  
**A01N 43/04** (2006.01); **A61K 31/195** (2006.01); **A61K 31/70** (2006.01); **A61P 3/04** (2006.01)

CPC (source: EP US)  
**A61K 31/195** (2013.01 - EP US); **A61P 3/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 7/12** (2017.12 - EP); **A61P 31/10** (2017.12 - EP); **A61P 33/00** (2017.12 - EP); **A61P 33/06** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **Y02A 50/30** (2017.12 - EP)

Citation (applicant)  
• WO 0050032 A1 20000831 - PHARMACIA & UPJOHN SPA [IT], et al  
• US 6284781 B1 20010904 - DANISHEFSKY SAMUEL J [US], et al  
• US 6288237 B1 20010911 - HOEFLE GERHARD [DE], et al  
• WO 0130768 A1 20010503 - CYTOKINETICS INC [US], et al  
• WO 0198278 A1 20011227 - CYTOKINETICS INC [US], et al  
• WO 03050064 A2 20030619 - MERCK & CO INC [US], et al  
• WO 03050122 A2 20030619 - MERCK & CO INC [US], et al  
• WO 03049527 A2 20030619 - MERCK & CO INC [US], et al  
• WO 03049679 A2 20030619 - MERCK & CO INC [US], et al  
• WO 03049678 A2 20030619 - MERCK & CO INC [US], et al  
• WO 03039460 A2 20030515 - MERCK & CO INC [US], et al  
• US 0306403 W 20030304  
• US 0315861 W 20030519  
• US 0315810 W 20030519  
• US 0318482 W 20030612  
• US 0318694 W 20030612  
• US 4231938 A 19801104 - MONAGHAN RICHARD L, et al  
• US 4294926 A 19811013 - MONAGHAN RICHARD L, et al  
• US 4319039 A 19820309 - ALBERS-SCHONBERG GEORGE  
• US 4444784 A 19840424 - HOFFMAN WILLIAM F [US], et al  
• US 4820850 A 19890411 - VERHOEVEN THOMAS R [US], et al  
• US 4916239 A 19900410 - TREIBER LASZLO R [US]  
• US 4346227 A 19820824 - TERAHARA AKIRA, et al  
• US 4537859 A 19850827 - TERAHARA AKIRA [JP], et al  
• US 4410629 A 19831018 - TERAHARA AKIRA [JP], et al  
• US 5030447 A 19910709 - JOSHI YATINDRA M [US], et al  
• US 5180589 A 19930119 - JOSHI YATINDRA M [US], et al  
• US 5354772 A 19941011 - KATHAWALA FAIZULLA G [US]  
• US 4911165 A 19900327 - LENNARD DAVID J [US], et al  
• US 4929437 A 19900529 - TOBERT JONATHAN A [US]  
• US 5189164 A 19930223 - KAPA PRASAD K [US], et al  
• US 5118853 A 19920602 - LEE GEORGE T [US], et al  
• US 5290946 A 19940301 - LEE GEORGE T [US], et al  
• US 5356896 A 19941018 - KABADI MOHAN B [US], et al  
• US 5273995 A 19931228 - ROTH BRUCE D [US]  
• US 4681893 A 19870721 - ROTH BRUCE D [US]  
• US 5489691 A 19960206 - BUTLER DONALD E [US], et al  
• US 5342952 A 19940830 - BUTLER DONALD E [US], et al  
• US 4782084 A 19881101 - VYAS KAMLESH P [US], et al  
• US 4885314 A 19891205 - VYAS KAMLESH P [US], et al  
• WO 9630343 A1 19961003 - MERCK & CO INC [US], et al  
• WO 9718813 A1 19970529 - MERCK & CO INC [US], et al  
• WO 9721701 A1 19970619 - JANSSEN PHARMACEUTICA NV [BE], et al  
• WO 9723478 A1 19970703 - SCHERING CORP [US]  
• WO 9738665 A2 19971023 - MERCK & CO INC [US], et al  
• WO 9828980 A1 19980709 - MERCK & CO INC [US], et al  
• WO 9829119 A1 19980709 - MERCK & CO INC [US], et al  
• WO 9532987 A1 19951207 - ISIS PHARMACEUTICALS INC [US], et al  
• US 5420245 A 19950530 - BROWN MICHAEL S [US], et al  
• US 5523430 A 19960604 - PATEL DINESH V [US], et al  
• US 5532359 A 19960702 - MARSTERS JR JAMES C [US], et al  
• US 5510510 A 19960423 - PATEL DINESH V [US], et al

- US 5589485 A 19961231 - HOCHLOWSKI JILL E [US], et al
- US 5602098 A 19970211 - SEBTI SAID [US], et al
- EP 0618221 A2 19941005 - BRISTOL MYERS SQUIBB CO [US]
- EP 0675112 A1 19951004 - BRISTOL MYERS SQUIBB CO [US]
- EP 0604181 A1 19940629 - LILLY CO ELI [US]
- EP 0696593 A2 19960214 - BRISTOL MYERS SQUIBB CO [US]
- WO 9419357 A1 19940901 - MERRELL DOW PHARMA [US], et al
- WO 9508542 A1 19950330 - KYOWA HAKKO KOGYO KK [JP], et al
- WO 9511917 A1 19950504 - PARKE DAVIS & CO [US]
- WO 9512612 A1 19950511 - WARNER LAMBERT CO [US]
- WO 9512572 A1 19950511 - ABBOTT LAB [US]
- WO 9510514 A1 19950420 - SCHERING CORP [US]
- US 5661152 A 19970826 - BISHOP W ROBERT [US], et al
- WO 9510515 A1 19950420 - SCHERING CORP [US]
- WO 9510516 A1 19950420 - SCHERING CORP [US]
- WO 9524612 A1 19950914 - IBM [US], et al
- WO 9534535 A1 19951221 - RHONE POULENC RORER SA [FR], et al
- WO 9525086 A1 19950921 - EISAI CO LTD [JP], et al
- WO 9605529 A1 19960222 - MICRON OPTICS INC [US]
- WO 9606138 A1 19960229 - SUEDEDEUTSCHE KALKSTICKSTOFF [DE], et al
- WO 9606193 A1 19960229 - MORE ANTON [DE]
- WO 9616443 A1 19960530 - PHILIPS ELECTRONICS NV [NL], et al
- WO 9621701 A2 19960718 - MAGLA INT LTD [US], et al
- WO 9621456 A1 19960718 - UNIV PITTSBURGH [US]
- WO 9622278 A1 19960725 - RHONE POULENC RORER SA [FR], et al
- WO 9624611 A1 19960815 - RHONE POULENC RORER SA [FR], et al
- WO 9624612 A1 19960815 - RHONE POULENC RORER SA [FR], et al
- WO 9605168 A1 19960222 - BANYU PHARMA CO LTD [JP], et al
- WO 9605169 A1 19960222 - BANYU PHARMA CO LTD [JP], et al
- WO 9600736 A1 19960111 - WARNER LAMBERT CO [US]
- US 5571792 A 19961105 - BOLTON GARY L [US], et al
- WO 9617861 A1 19960613 - WARNER LAMBERT CO [US]
- WO 9633159 A1 19961024 - ABBOTT LAB [US]
- WO 9634850 A1 19961107 - ABBOTT LAB [US]
- WO 9634851 A1 19961107 - ABBOTT LAB [US]
- WO 9630017 A1 19961003 - SCHERING CORP [US]
- WO 9630018 A1 19961003 - SCHERING CORP [US]
- WO 9630362 A1 19961003 - SCHERING CORP [US]
- WO 9630363 A1 19961003 - SCHERING CORP [US]
- WO 9631111 A1 19961010 - SCHERING CORP [US]
- WO 9631477 A1 19961010 - SCHERING CORP [US]
- WO 9631478 A1 19961010 - SCHERING CORP [US], et al
- WO 9631501 A1 19961010 - SCHERING CORP [US], et al
- WO 9700252 A1 19970103 - WARNER LAMBERT CO [US], et al
- WO 9703047 A1 19970130 - RHONE POULENC RORER SA [FR], et al
- WO 9703050 A1 19970130 - RHONE POULENC RORER SA [FR], et al
- WO 9704785 A1 19970213 - SYMPHAR SA [CH], et al
- WO 9702920 A1 19970130 - DATACON SCHWEITZER & ZEINDL GM [AT], et al
- WO 9717070 A1 19970515 - UNIV PITTSBURGH [US]
- WO 9726246 A1 19970724 - WARNER LAMBERT CO [US], et al
- WO 9730053 A1 19970821 - BIOMEASURE INC [US]
- WO 9744350 A1 19971127 - WARNER LAMBERT CO [US], et al
- WO 9802436 A1 19980122 - BRISTOL MYERS SQUIBB CO [US]
- WO 0044777 A1 20000803 - IMCLONE SYSTEMS INC [US], et al
- WO 0061186 A1 20001019 - WEICHSELBAUM RALPH R [US]
- WO 03013526 A1 20030220 - MERCK & CO INC [US], et al
- WO 03086404 A1 20031023 - MERCK & CO INC [US], et al
- WO 03086403 A1 20031023 - MERCK & CO INC [US], et al
- WO 03086394 A1 20031023 - MERCK & CO INC [US], et al
- WO 03086279 A2 20031023 - MERCK & CO INC [US], et al
- WO 02083675 A2 20021024 - MERCK SHARP & DOHME [GB], et al
- WO 02083139 A1 20021024 - MERCK & CO INC [US], et al
- WO 02083140 A1 20021024 - MERCK & CO INC [US], et al
- WO 02083138 A1 20021024 - MERCK & CO INC [US], et al
- US 5474995 A 19951212 - DUCHARME YVES [CA], et al
- US 5861419 A 19990119 - DUBE DANIEL [CA], et al
- US 6001843 A 19991214 - DUBE DANIEL [CA], et al
- US 6020343 A 20000201 - BELLEY MICHEL [CA], et al
- US 5409944 A 19950425 - BLACK W CAMERON [CA], et al
- US 5436265 A 19950725 - BLACK CAMERON [CA], et al
- US 5536752 A 19960716 - DUCHARME YVES [CA], et al
- US 5550142 A 19960827 - DUCHARME YVES [CA], et al
- US 5604260 A 19970218 - GUAY DANIEL [CA], et al
- US 5698584 A 19971216 - BLACK CAMERON [CA], et al
- US 5710140 A 19980120 - DUCHARME YVES [CA], et al
- WO 9415932 A1 19940721 - SEARLE & CO [US], et al
- US 5344991 A 19940906 - REITZ DAVID B [US], et al
- US 5134142 A 19920728 - MATSUO MASAOKI [JP], et al
- US 5380738 A 19950110 - NORMAN BRYAN H [US], et al
- US 5393790 A 19950228 - REITZ DAVID B [US], et al
- US 5466823 A 19951114 - TALLEY JOHN J [US], et al
- US 5633272 A 19970527 - TALLEY JOHN J [US], et al
- US 5932598 A 19990803 - TALLEY JOHN J [US], et al

- WO 9710813 A1 19970327 - LIGAND PHARM INC [US]
- WO 9727857 A1 19970807 - MERCK & CO INC [US], et al
- WO 9728115 A1 19970807 - MERCK & CO INC [US], et al
- WO 9728137 A1 19970807 - MERCK & CO INC [US], et al
- WO 9727847 A1 19970807 - MERCK & CO INC [US], et al
- WO 9736579 A1 19971009 - GLAXO GROUP LTD [GB], et al
- WO 9728149 A1 19970807 - MERCK & CO INC [US], et al
- US 6414002 B1 20020702 - CHENG PETER T [US], et al
- US 5536716 A 19960716 - CHEN MENG-HSIN [US], et al
- US 6358951 B1 20020319 - CARPINO PHILIP A [US]
- US 2002049196 A1 20020425 - CARPINO PHILIP A [US], et al
- US 2002022637 A1 20020221 - LI JAMES J [US], et al
- WO 0156592 A1 20010809 - NOVO NORDISK AS [DK]
- WO 0232888 A1 20020425 - LILLY CO ELI [US], et al
- US 5532237 A 19960702 - GALLANT MICHEL [CA], et al
- US 4973587 A 19901127 - WARD SUSAN J [US], et al
- US 5013837 A 19910507 - WARD SUSAN J [US], et al
- US 5081122 A 19920114 - WARD SUSAN J [US]
- US 5112820 A 19920512 - WARD SUSAN J [US]
- US 5292736 A 19940308 - KUMAR VIRENDRA [US], et al
- US 5624941 A 19970429 - BARTH FRANCIS [FR], et al
- US 6028084 A 20000222 - BARTH FRANCIS [FR], et al
- WO 9833765 A1 19980806 - DU PONT [US], et al
- WO 9843636 A1 19981008 - SANOFI SA [FR], et al
- WO 9843635 A1 19981008 - SANOFI SA [FR], et al
- WO 0109120 A1 20010208 - ORTHO MCNEIL PHARM INC [US]
- WO 9831227 A1 19980723 - SMITHKLINE BEECHAM CORP [US], et al
- WO 9841519 A1 19980924 - SMITHKLINE BEECHAM CORP [US], et al
- WO 9837061 A1 19980827 - BAYER AG [DE], et al
- WO 0010967 A1 20000302 - BAYER AG [DE], et al
- WO 0010968 A2 20000302 - BAYER AG [DE], et al
- WO 9729079 A1 19970814 - JAPAN TOBACCO INC [JP], et al
- WO 9902499 A1 19990121 - JAPAN TOBACCO INC [JP], et al
- WO 0158869 A2 20010816 - BRISTOL MYERS SQUIBB CO [US], et al
- WO 0164632 A1 20010907 - AVENTIS PHARMA SA [FR]
- WO 0164633 A1 20010907 - AVENTIS PHARMA SA [FR]
- WO 0164634 A1 20010907 - AVENTIS PHARMA SA [FR]
- WO 02076949 A1 20021003 - SOLVAY PHARM BV [NL], et al
- WO 03007887 A2 20030130 - MERCK & CO INC [US], et al
- WO 2004048317 A1 20040610 - MERCK & CO INC [US], et al
- WO 2005000809 A1 20050106 - MERCK & CO INC [US], et al
- EP 0658546 A1 19950621 - SANOFI SA [FR]
- EP 0656354 A1 19950607 - SANOFI SA [FR]
- EP 0576357 A1 19931229 - SANOFI ELF [FR]
- US 5705515 A 19980106 - FISHER MICHAEL H [US], et al
- US 5451677 A 19950919 - FISHER MICHAEL H [US], et al
- WO 9418161 A1 19940818 - MERCK & CO INC [US], et al
- WO 9529159 A1 19951102 - MERCK & CO INC [US], et al
- WO 9746556 A1 19971211 - MERCK & CO INC [US], et al
- WO 9804526 A1 19980205 - MERCK & CO INC [US], et al
- WO 9832753 A1 19980730 - MERCK & CO INC [US], et al
- WO 0174782 A1 20011011 - MOLECULAR DESIGN INT [US], et al
- WO 0232897 A1 20020425 - PFIZER PROD INC [US], et al
- WO 0177094 A1 20011018 - AVENTIS PHARMA GMBH [DE]
- US 6001836 A 19991214 - POINDEXTER GRAHAM S [US], et al
- WO 9614307 A1 19960517 - PFIZER [US], et al
- WO 0123387 A2 20010405 - NEUROGEN CORP [US], et al
- WO 9951600 A1 19991014 - NEUROGEN CORP [US], et al
- WO 0185690 A1 20011115 - BRISTOL MYERS SQUIBB CO [US]
- WO 0185098 A2 20011115 - BRISTOL MYERS SQUIBB CO [US]
- WO 0185173 A1 20011115 - BRISTOL MYERS SQUIBB CO [US]
- WO 0189528 A1 20011129 - BRISTOL MYERS SQUIBB CO [US]
- US 6057335 A 20000502 - FUKAMI TAKEHIRO [JP], et al
- US 6043246 A 20000328 - FUKAMI TAKEHIRO [JP], et al
- US 6140354 A 20001031 - DAX SCOTT L [US], et al
- US 6166038 A 20001226 - FUKAMI TAKEHIRO [JP], et al
- US 6180653 B1 20010130 - FUKAMI TAKEHIRO [JP], et al
- US 6191160 B1 20010220 - GAO YING-DUO [US], et al
- US 6313298 B1 20011106 - GAO YING-DUO [US], et al
- US 6335345 B1 20020101 - FUKAMI TAKEHIRO [JP], et al
- US 6337332 B1 20020108 - CARPINO PHILIP A [US]
- US 6326375 B1 20011204 - FUKAMI TAKEHIRO [JP], et al
- US 6329395 B1 20011211 - DUGAR SUNDEEP [US], et al
- US 6340683 B1 20020122 - MARZABADI MOHAMMAD R [US], et al
- US 6388077 B1 20020514 - FUKAMI TAKEHIRO [JP], et al
- US 6462053 B1 20021008 - FUKAMI TAKEHIRO [JP], et al
- US 6649624 B2 20031118 - FUKAMI TAKEHIRO [JP], et al
- US 6723847 B2 20040420 - FUKAMI TAKEHIRO [JP], et al
- EP 1010691 A2 20000621 - ADIR [FR]
- EP 1044970 A1 20001018 - ADIR [FR]
- WO 9719682 A1 19970605 - SYNAPTIC PHARMA CORP [US], et al
- WO 9720820 A1 19970612 - CIBA GEIGY AG [CH], et al
- WO 9720821 A1 19970612 - CIBA GEIGY AG [CH], et al

- WO 9720822 A1 19970612 - CIBA GEIGY AG [CH], et al
- WO 9720823 A2 19970612 - CIBA GEIGY AG [CH], et al
- WO 9824768 A1 19980611 - BANYU PHARMA CO LTD [JP], et al
- WO 9825907 A1 19980618 - BANYU PHARMA CO LTD [JP], et al
- WO 9825908 A1 19980618 - BANYU PHARMA CO LTD [JP], et al
- WO 9827063 A1 19980625 - BANYU PHARMA CO LTD [JP], et al
- WO 9847505 A1 19981029 - BANYU PHARMA CO LTD [JP], et al
- WO 9840356 A1 19980917 - BANYU PHARMA CO LTD [JP], et al
- WO 9915516 A1 19990401 - BANYU PHARMA CO LTD [JP], et al
- WO 9927965 A1 19990610 - BANYU PHARMA CO LTD [JP], et al
- WO 0064880 A1 20001102 - SYNAPTIC PHARMA CORP [US], et al
- WO 0068197 A1 20001116 - ORTHO MCNEIL PHARM INC [US]
- WO 0069849 A1 20001123 - ORTHO MCNEIL PHARM INC [US]
- WO 0114376 A1 20010301 - BANYU PHARMA CO LTD [JP], et al
- WO 0185714 A1 20011115 - ASTRAZENECA AB [SE], et al
- WO 0185730 A1 20011115 - ASTRAZENECA AB [SE], et al
- WO 0107409 A1 20010201 - ASTRAZENECA UK LTD [GB], et al
- WO 0102379 A1 20010111 - SYNAPTIC PHARMA CORP [US], et al
- WO 0123388 A2 20010405 - NEUROGEN CORP [US], et al
- WO 0123389 A2 20010405 - NEUROGEN CORP [US], et al
- WO 0144201 A1 20010621 - SCHERING CORP [US], et al
- WO 0162737 A2 20010830 - ORTHO MCNEIL PHARM INC [US]
- WO 0162738 A1 20010830 - BANYU PHARMA CO LTD [JP], et al
- WO 0222592 A2 20020321 - SCHERING CORP [US]
- WO 0248152 A2 20020620 - NEUROGEN CORP [US], et al
- WO 0249648 A1 20020627 - SCHERING CORP [US]
- WO 02094825 A1 20021128 - BANYU PHARMA CO LTD [JP], et al
- WO 03014083 A1 20030220 - BANYU PHARMA CO LTD [JP], et al
- WO 03010191 A1 20030206 - EMBRAPA PESQUISA AGROPECUARIA [BR], et al
- WO 03092889 A1 20031113 - BANYU PHARMA CO LTD [JP], et al
- WO 2004002986 A2 20040108 - BANYU PHARMA CO LTD [JP], et al
- WO 2004031175 A2 20040415 - BANYU PHARMA CO LTD [JP], et al
- WO 0121577 A2 20010329 - TAKEDA CHEMICAL INDUSTRIES LTD [JP], et al
- WO 0121169 A1 20010329 - TAKEDA CHEMICAL INDUSTRIES LTD [JP], et al
- WO 0182925 A1 20011108 - TAKEDA CHEMICAL INDUSTRIES LTD [JP], et al
- WO 0187834 A1 20011122 - TAKEDA CHEMICAL INDUSTRIES LTD [JP], et al
- WO 02051809 A1 20020704 - SCHERING CORP [US]
- WO 0206245 A1 20020124 - SYNAPTIC PHARMACEUTICAL CORP [US]
- WO 02076929 A1 20021003 - PHARMACOEPIA INC [US]
- WO 02076947 A1 20021003 - SCHERING CORP [US]
- WO 0204433 A2 20020117 - NEUROGEN CORP [US], et al
- WO 02051809 A1 20020704 - SCHERING CORP [US]
- WO 02083134 A1 20021024 - PHARMACOEPIA INC [US]
- WO 02094799 A2 20021128 - NEUROGEN CORP [US], et al
- WO 03004027 A1 20030116 - SYNAPTIC PHARMA CORP [US]
- JP 2001226269 A 20010821 - TAKEDA CHEMICAL INDUSTRIES LTD
- JP 2004139909 A 20040513 - TOSHIBA BATTERY
- WO 0196302 A1 20011220 - SMITHKLINE BEECHAM PLC [GB], et al
- WO 0168609 A1 20010920 - ACTELION PHARMACEUTICALS LTD [CH], et al
- WO 02051232 A2 20020704 - ACTELION PHARMACEUTICALS LTD [CH]
- WO 02051838 A1 20020704 - ACTELION PHARMACEUTICALS LTD [CH], et al
- US 6365633 B1 20020402 - CHEETHAM SHARON C [GB], et al
- WO 0127060 A1 20010419 - HAARMANN & REIMER GMBH [DE], et al
- WO 0162341 A2 20010830 - KNOLL AG [DE], et al
- WO 9964002 A1 19991216 - MERCK & CO INC [US], et al
- WO 0074679 A1 20001214 - MERCK & CO INC [US], et al
- US 6410548 B2 20020625 - NARGUND RAVI P [US], et al
- US 6294534 B1 20010925 - NARGUND RAVI P [US], et al
- US 6350760 B1 20020226 - BAKSHI RAMAN K [US], et al
- US 6458790 B2 20021001 - PALUCKI BRENDA L [US], et al
- US 6472398 B1 20021029 - PALUCKI BRENDA L [US], et al
- US 6376509 B2 20020423 - BAKSHI RAMAN KUMAR [US], et al
- US 6818658 B2 20041116 - UJJAINWALLA FEROZE [US], et al
- US 2002137664 A1 20020926 - BAKSHI RAMAN K [US], et al
- US 2003236262 A1 20031225 - BAKSHI RAMAN K [US], et al
- US 2004009751 A1 20040115 - MICHAELIS OLIVER [US], et al
- US 2004092501 A1 20040513 - GOULET MARK T [US], et al
- WO 0170708 A1 20010927 - MERCK & CO INC [US], et al
- WO 0170337 A1 20010927 - MERCK & CO INC [US], et al
- WO 0174844 A2 20011011 - HOFFMANN LA ROCHE [CH]
- WO 0191752 A1 20011206 - MERCK & CO INC [US], et al
- WO 0215909 A1 20020228 - MERCK & CO INC [US], et al
- WO 02059095 A1 20020801 - LILLY CO ELI [US], et al
- WO 02059107 A1 20020801 - LILLY CO ELI [US], et al
- WO 02059108 A1 20020801 - LILLY CO ELI [US], et al
- WO 02059117 A1 20020801 - LILLY CO ELI [US], et al
- WO 02067869 A2 20020906 - MERCK & CO INC [US], et al
- WO 02068387 A2 20020906 - MERCK & CO INC [US], et al
- WO 02068388 A2 20020906 - MERCK & CO INC [US], et al
- WO 0211715 A2 20020214 - MELACURE THERAPEUTICS AB [SE], et al
- WO 0212166 A2 20020214 - LION BIOSCIENCE AG [DE], et al
- WO 0212178 A1 20020214 - MELACURE THERAPEUTICS AB [SE], et al
- WO 03007949 A1 20030130 - MERCK & CO INC [US], et al

- WO 03009847 A1 20030206 - AMGEM INC [US]
- WO 2004024720 A1 20040325 - MERCK & CO INC [US], et al
- WO 2004078716 A1 20040916 - MERCK & CO INC [US], et al
- WO 2004078717 A1 20040916 - MERCK & CO INC [US], et al
- WO 2004087159 A1 20041014 - MERCK & CO INC [US], et al
- WO 2004089307 A2 20041021 - MERCK & CO INC [US], et al
- WO 2005009950 A2 20050203 - MERCK & CO INC [US], et al
- US 3914250 A 19751021 - KIM DONG H
- WO 0236596 A2 20020510 - WYETH CORP [US]
- WO 0248124 A2 20020620 - HOFFMANN LA ROCHE [CH], et al
- WO 0210169 A1 20020207 - HOFFMANN LA ROCHE [CH], et al
- WO 0166548 A1 20010913 - HOFFMANN LA ROCHE [CH], et al
- WO 0244152 A1 20020606 - HOFFMANN LA ROCHE [CH], et al
- WO 02051844 A1 20020704 - HOFFMANN LA ROCHE [CH], et al
- WO 0240456 A1 20020523 - BIOVITRUM AB [SE], et al
- WO 0240457 A1 20020523 - BIOVITRUM AB [SE], et al
- US 5739106 A 19980414 - RINK TIMOTHY J [US], et al
- WO 0215905 A1 20020228 - GLIATECH INC [US], et al
- WO 0187335 A2 20011122 - LILLY CO ELI [US], et al
- WO 0208250 A2 20020131 - ZENTARIS AG [DE]
- US 5552524 A 19960903 - BASINSKI MARGRET B [US], et al
- US 5552523 A 19960903 - BASINSKI MARGRET B [US], et al
- US 5552522 A 19960903 - DIMARCHI RICHARD D [US], et al
- US 5521283 A 19960528 - DIMARCHI RICHARD D [US], et al
- WO 9623513 A1 19960808 - LILLY CO ELI [US], et al
- WO 9623514 A1 19960808 - LILLY CO ELI [US], et al
- WO 9623515 A1 19960808 - LILLY CO ELI [US], et al
- WO 9623516 A1 19960808 - LILLY CO ELI [US], et al
- WO 9623517 A1 19960808 - LILLY CO ELI [US], et al
- WO 9623518 A1 19960808 - LILLY CO ELI [US], et al
- WO 9623519 A1 19960808 - LILLY CO ELI [US], et al
- WO 9623520 A1 19960808 - LILLY CO ELI [US], et al
- WO 9409134 A2 19940428 - REGENERON PHARMA [US]
- WO 9822128 A1 19980528 - ANGELETTI P IST RICHERCHE BIO [IT], et al
- WO 9943813 A1 19990902 - REGENERON PHARMA [US], et al
- US 4746680 A 19880524 - JEFFERY JAMES E [GB], et al
- US 4806570 A 19890221 - JEFFERY JAMES E [GB], et al
- US 5436272 A 19950725 - SCHEINBAUM MONTE L [US]
- US 2002006964 A1 20020117 - YOUNG JAMES W [US], et al
- WO 0127068 A1 20010419 - PFIZER PROD INC [US], et al
- WO 0162341 A2 20010830 - KNOLL AG [DE], et al
- WO 9900123 A1 19990107 - PHARMACIA & UPJOHN AB [SE], et al
- WO 0215845 A2 20020228 - MERCK & CO INC [US], et al
- JP 2000256190 A 20000919 - PFIZER PROD INC
- US 6699871 B2 20040302 - EDMONDSON SCOTT D [US], et al
- WO 03004498 A1 20030116 - MERCK & CO INC [US], et al
- WO 03004496 A1 20030116 - NOVO NORDISK AS [DK]
- EP 1258476 A1 20021120 - SERVIER LAB [FR]
- WO 02083128 A1 20021024 - BRISTOL MYERS SQUIBB CO [US], et al
- WO 02062764 A1 20020815 - TAKEDA CHEMICAL INDUSTRIES LTD [JP], et al
- WO 03000250 A1 20030103 - FERRING BV [NL], et al
- WO 03002530 A2 20030109 - SMITHKLINE BEECHAM CORP [US], et al
- WO 03002531 A2 20030109 - SMITHKLINE BEECHAM CORP [US], et al
- WO 03002553 A2 20030109 - SMITHKLINE BEECHAM CORP [US], et al
- WO 03002593 A2 20030109 - PROBIODRUG AG [DE], et al
- WO 03000180 A2 20030103 - MERCK & CO INC [US], et al
- WO 03000181 A2 20030103 - MERCK & CO INC [US], et al
- US 5026685 A 19910625 - BOUBLIK JAROSLAV H [US], et al
- US 5604203 A 19970218 - BALASUBRAMANIAM AMBIKAIPAKAN [US]
- US 5574010 A 19961112 - MCFADDEN DAVID W [US]
- US 5696093 A 19971209 - TSENG ALBERT [AU], et al
- US 5936092 A 19990810 - SHEN WEI-CHIANG [US], et al
- US 6046162 A 20000404 - RUOSLAHTI ERKKI I [US], et al
- US 6046167 A 20000404 - BALASUBRAMANIAM AMBIKAIPAKAN [US]
- US 6093692 A 20000725 - SHEN WEI-CHIANG [US], et al
- US 6225445 B1 20010501 - SHEN WEI-CHIANG [US], et al
- US 4002531 A 19770111 - ROYER GARFIELD P
- US 4179337 A 19791218 - DAVIS FRANK F [US], et al
- US 5122614 A 19920616 - ZALIPSKY SHMUEL [US]
- US 5349052 A 19940920 - DELGADO CRISTINA [GB], et al
- US 5552520 A 19960903 - KIM SUN H [US], et al
- US 6127355 A 20001003 - GREENWALD RICHARD B [US], et al
- WO 9506058 A1 19950302 - ROYAL FREE HOSP SCHOOL MED [GB], et al
- WO 9832466 A1 19980730 - POLYMASC PHARMACEUTICALS PLC [GB], et al
- WO 03026591 A2 20030403 - IMP COLLEGE INNOVATIONS LTD [GB], et al
- WO 03057235 A2 20030717 - IMP COLLEGE INNOVATIONS LTD [GB], et al
- WO 03027637 A2 20030403 - UNIV OREGON HEALTH & SCIENCE [US], et al
- WO 2004066966 A2 20040812 - SOD CONSEILS RECH APPLIC [FR], et al
- WO 0021509 A2 20000420 - IMP COLLEGE INNOVATIONS LTD [GB], et al
- WO 0190091 A1 20011129 - BIOVITRUM AB [SE], et al
- WO 0190090 A1 20011129 - BIOVITRUM AB [SE], et al
- WO 0190092 A1 20011129 - BIOVITRUM AB [SE], et al
- US 6730690 B2 20040504 - OLSON STEVEN H [US], et al

- US 2004133011 A1 20040708 - WADDELL SHERMAN T [US], et al
- US 5162339 A 19921110 - LOWE III JOHN A [US]
- US 5232929 A 19930803 - DESAI MANOJ C [US], et al
- US 5242930 A 19930907 - BAKER RAYMOND [GB], et al
- US 5373003 A 19941213 - LOWE III JOHN A [US]
- US 5387595 A 19950207 - MILLS SANDER G [US], et al
- US 5459270 A 19951017 - WILLIAMS BRIAN [GB], et al
- US 5494926 A 19960227 - OWENS ANDREW P [GB], et al
- US 5496833 A 19960305 - BAKER REYMOND [GB], et al
- US 5637699 A 19970610 - DORN CONRAD P [US], et al
- WO 9005525 A1 19900531 - PFIZER [US]
- WO 9005729 A1 19900531 - PFIZER [US]
- WO 9109844 A1 19910711 - PFIZER [US]
- WO 9118899 A1 19911212 - PFIZER [US]
- WO 9201688 A1 19920206 - PFIZER [US]
- WO 9206079 A1 19920416 - PFIZER [US]
- WO 9212151 A1 19920723 - PFIZER [US]
- WO 9215585 A1 19920917 - PFIZER [US]
- WO 9217449 A1 19921015 - PFIZER [US]
- WO 9220661 A1 19921126 - MERCK & CO INC [US]
- WO 9220676 A1 19921126 - PFIZER [US]
- WO 9221677 A1 19921210 - PFIZER [US]
- WO 9222569 A1 19921223 - FUJISAWA PHARMACEUTICAL CO [JP]
- WO 9300330 A2 19930107 - PFIZER [US]
- WO 9300331 A1 19930107 - PFIZER [US]
- WO 9301159 A1 19930121 - MERCK SHARP & DOHME [GB]
- WO 9301165 A2 19930121 - MERCK SHARP & DOHME [GB]
- WO 9301169 A2 19930121 - MERCK SHARP & DOHME [GB]
- WO 9301170 A1 19930121 - PFIZER [US]
- WO 9306099 A1 19930401 - PFIZER [US]
- WO 9309116 A1 19930513 - YOSHITOMI PHARMACEUTICAL [JP]
- WO 9310073 A1 19930527 - PFIZER [US]
- WO 9314084 A2 19930722 - GLAXO GROUP LTD [GB]
- WO 9314113 A1 19930722 - FUJISAWA PHARMACEUTICAL CO [JP]
- WO 9318023 A1 19930916 - MERCK SHARP & DOHME [GB]
- WO 9319064 A1 19930930 - PFIZER [US]
- WO 9321155 A1 19931028 - RHONE POULENC RORER SA [FR], et al
- WO 9321181 A1 19931028 - MERCK SHARP & DOHME [GB], et al
- WO 9323380 A1 19931125 - PFIZER [US], et al
- WO 9324465 A1 19931209 - MERCK SHARP & DOHME [GB], et al
- WO 9400440 A1 19940106 - MERCK & CO INC [US], et al
- WO 9401402 A1 19940120 - MERCK SHARP & DOHME [GB], et al
- WO 9402461 A1 19940203 - MERCK SHARP & DOHME [GB], et al
- WO 9402595 A1 19940203 - RIBOZYME PHARM INC [US]
- WO 9403429 A1 19940217 - MERCK SHARP & DOHME [GB], et al
- WO 9403445 A1 19940217 - PFIZER [US], et al
- WO 9404494 A1 19940303 - WARNER LAMBERT CO [US]
- WO 9404496 A1 19940303 - PFIZER [US], et al
- WO 9405625 A1 19940317 - MERCK SHARP & DOHME [GB], et al
- WO 9407843 A1 19940414 - MERCK SHARP & DOHME [GB], et al
- WO 9408997 A1 19940428 - PFIZER [US], et al
- WO 9410165 A1 19940511 - MERCK SHARP & DOHME [GB], et al
- WO 9410167 A1 19940511 - MERCK SHARP & DOHME [GB], et al
- WO 9410168 A1 19940511 - MERCK SHARP & DOHME [GB], et al
- WO 9410170 A1 19940511 - PFIZER [US], et al
- WO 9411368 A1 19940526 - PFIZER [US], et al
- WO 9413639 A1 19940623 - MERCK SHARP & DOHME [GB], et al
- WO 9413663 A1 19940623 - PFIZER [US], et al
- WO 9414767 A1 19940707 - MERCK SHARP & DOHME [GB], et al
- WO 9415903 A1 19940721 - MERCK SHARP & DOHME [GB], et al
- WO 9419320 A1 19940901 - MERCK SHARP & DOHME [GB], et al
- WO 9419323 A1 19940901 - MERCK SHARP & DOHME [GB], et al
- WO 9420500 A1 19940915 - PFIZER [US], et al
- WO 9426735 A1 19941124 - MERRELL DOW PHARMA [US], et al
- WO 9426740 A1 19941124 - PFIZER PHARMA [JP], et al
- WO 9429309 A1 19941222 - MERCK & CO INC [US], et al
- WO 9502595 A1 19950126 - PFIZER PHARMA [JP], et al
- WO 9504040 A1 19950209 - RHONE POULENC RORER SA [FR], et al
- WO 9504042 A1 19950209 - MERCK SHARP & DOHME [GB], et al
- WO 9506645 A1 19950309 - GLAXO GROUP LTD [GB], et al
- WO 9507886 A1 19950323 - PFIZER [US], et al
- WO 9507908 A1 19950323 - PFIZER [US], et al
- WO 9508549 A1 19950330 - GLAXO GROUP LTD [GB], et al
- WO 9511880 A1 19950504 - MERCK SHARP & DOHME [GB], et al
- WO 9514017 A1 19950526 - LILLY CO ELI [US]
- WO 9515311 A1 19950608 - MENARINI FARMA IND [IT], et al
- WO 9516679 A1 19950622 - MERCK & CO INC [US], et al
- WO 9517382 A1 19950629 - LILLY CO ELI [US]
- WO 9518124 A1 19950706 - MERCK SHARP & DOHME [GB], et al
- WO 9518129 A1 19950706 - PFIZER [US], et al
- WO 9519344 A1 19950720 - MERCK SHARP & DOHME [GB], et al
- WO 9520575 A1 19950803 - MERCK SHARP & DOHME [GB], et al
- WO 9521819 A1 19950817 - MERCK SHARP & DOHME [GB], et al

- WO 9522525 A1 19950824 - MERCK & CO INC [US], et al
- WO 9523798 A1 19950908 - MERCK & CO INC [US], et al
- WO 9526338 A1 19951005 - SANOFI SA [FR], et al
- WO 9528418 A2 19951026 - WARNER LAMBERT CO [US]
- WO 9530674 A1 19951116 - MERCK SHARP & DOHME [GB], et al
- WO 9530687 A1 19951116 - BOEHRINGER INGELHEIM KG [DE], et al
- WO 9533744 A1 19951214 - WARNER LAMBERT CO [US]
- WO 9605181 A1 19960222 - MERCK SHARP & DOHME [GB], et al
- WO 9605193 A1 19960222 - PFIZER LTD [GB], et al
- WO 9605203 A1 19960222 - MERCK SHARP & DOHME [GB], et al
- WO 9606094 A1 19960229 - MERRELL DOW PHARMA [US]
- WO 9607649 A1 19960314 - MERCK SHARP & DOHME [GB], et al
- WO 9610562 A1 19960411 - CIBA GEIGY AG [CH], et al
- WO 9616939 A1 19960606 - RHONE-POULENC RORER SA [FR], et al
- WO 9618643 A1 19960620 - SANDOZ LTD [CH], et al
- WO 9620197 A1 19960704 - MERCK SHARP & DOHME [GB], et al
- WO 9621661 A1 19960718 - GLAXO GROUP LTD [GB], et al
- WO 9629304 A1 19960926 - WARNER LAMBERT CO [US]
- WO 9629317 A1 19960926 - MERCK SHARP & DOHME [GB], et al
- WO 9629326 A1 19960926 - GLAXO GROUP LTD [GB], et al
- WO 9629328 A1 19960926 - MERCK SHARP & DOHME [GB], et al
- WO 9631214 A1 19961010 - LILLY CO ELI [US]
- WO 9632385 A1 19961017 - HOECHST MARION ROUSSEL INC [US]
- WO 9637489 A1 19961128 - FUJISAWA PHARMACEUTICAL CO [JP]
- WO 9701553 A1 19970116 - MERCK SHARP & DOHME [GB], et al
- WO 9701554 A1 19970116 - MERCK SHARP & DOHME [GB], et al
- WO 9703066 A1 19970130 - PFIZER PHARMA [JP], et al
- WO 9708144 A1 19970306 - PFIZER PHARMA [JP], et al
- WO 9714671 A1 19970424 - MERCK & CO INC [US], et al
- WO 9717362 A1 19970515 - BOEHRINGER INGELHEIM KG [DE]
- WO 9718206 A1 19970522 - MERCK SHARP & DOHME [GB], et al
- WO 9719084 A1 19970529 - MERCK SHARP & DOHME [GB], et al
- WO 9719942 A1 19970605 - PFIZER LTD [GB], et al
- WO 9721702 A1 19970619 - MERCK SHARP & DOHME [GB], et al
- WO 9749710 A1 19971231 - MERCK SHARP & DOHME [GB], et al
- WO 03077847 A2 20030925 - MERCK & CO INC [US], et al
- WO 2005077905 A1 20050825 - BANYU PHARMA CO LTD [JP], et al
- RASHID, A. ET AL.: "Elevated expression of fatty acid synthase and fatty acid synthetase activity in colorectal neoplasia", AM JPATHOL, vol. 150, 1997, pages 201 - 8
- ALO, P. L. ET AL.: "Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients", CANCER, vol. 77, 1996, pages 474 - 82, XP002105051, DOI: doi:10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K
- JENSEN, V. ET AL.: "The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer", J PATHOL, vol. 176, 1995, pages 343 - 52
- PIZER, E. S. ET AL.: "Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors", CANCER, vol. 83, 1998, pages 528 - 37
- MILGRAUM, L. Z. ET AL.: "Enzymes of the fatty acid synthesis pathway are highly expressed in situ breast carcinoma", CLIN CANCER RES, vol. 3, 1997, pages 2115 - 20, XP001053474
- WAKIL, S. J.: "Fatty acid synthase, a proficient multifunctional enzyme", BIOCHEMISTRY, vol. 28, 1989, pages 4523 - 30, XP002016569, DOI: doi:10.1021/bi00437a001
- PIZER, E. S. ET AL.: "Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells", CANCER RES, vol. 56, 1996, pages 2745 - 7, XP000942097
- PIZER, E. S. ET AL.: "Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines", CANCER RES, vol. 58, 1998, pages 4611 - 5, XP000942095
- PIZER, E. S. ET AL.: "Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts", CANCER RES, vol. 60, 2000, pages 213 - 8, XP000983309
- KUHAJDA, F. P. ET AL.: "Synthesis and antitumor activity of an inhibitor of fatty acid synthase", PROC NATL ACAD SCI U S A, vol. 97, 2000, pages 3450 - 4, XP002397205, DOI: doi:10.1073/pnas.050582897
- ZHOU, W. ET AL.: "Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells", CANCER RES, vol. 63, 2003, pages 7330 - 7
- MENENDEZ, J. A. ET AL.: "Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB", INT J ONCOL, vol. 24, 2004, pages 591 - 608
- MENENDEZ, J. A. ET AL.: "Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel me", INT J ONCOL, vol. 24, 2004, pages 1369 - 83, XP009097853
- MENENDEZ, J. A. ET AL.: "Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells", PROC NATL ACAD SCI U S A, vol. 101, 2004, pages 10715 - 20, XP002571752, DOI: doi:10.1073/pnas.0403390101
- MENENDEZ, J. A. ET AL.: "Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation", MOL CARCINO, vol. 41, 2004, pages 164 - 78
- MENENDEZ, J. A.; LUPU, R.: "RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells", INT JMOT MED, vol. 15, 2005, pages 33 - 40
- MENENDEZ, J. A. ET AL.: "Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity", INT J CANCER, vol. 115, 2005, pages 19 - 35, XP002746381, DOI: doi:10.1002/ijc.20754
- MENENDEZ, J. A. ET AL.: "Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1 alpha (HIF-1alpha)-related expression of vascular endothelial growth factor", J CELL BIOCHEM, vol. 94, 2005, pages 857 - 63
- MENENDEZ, J. A. ET AL.: "The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival", INT J ONCOL, vol. 26, 2005, pages 1507 - 15
- LOFTUS, T. M. ET AL.: "Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors", SCIENCE, vol. 288, 2000, pages 2379 - 81, XP008039591, DOI: doi:10.1126/science.288.5475.2379
- PIZER, E. S.; LAX, S. F.; KUHAJDA, F. P.; PASTERNAK, G. R.; KURMAN, R. J.: "Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors", CANCER, vol. 83, 1998, pages 528 - 37

- OFTUS, T. M. ET AL.: "Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors", *SCIENCE*, vol. 288, 2000, pages 2379 - 81, XP008039591, DOI: doi:10.1126/science.288.5475.2379
- MAKIMURA, H. ET AL.: "Cerulein mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulein fails to block neuroendocrine effects of fasting", *DIABETES*, vol. 50, 2001, pages 733 - 9
- SHIMOKAWA, T. ET AL.: "Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides", *PROC NATL ACAD SCI U S A*, vol. 99, 2002, pages 66 - 71, XP002659620, DOI: doi:10.1073/pnas.012606199
- KUMAR, M. V ET AL.: "Differential effects of a centrally acting fatty acid synthase inhibitor in lean and obese mice", *PROC NATL ACAD SCI U S A*, vol. 99, 2002, pages 1921 - 5
- THUPARI, J. N. ET AL.: "C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity", *PROC NATL ACAD SCI U S A*, vol. 99, 2002, pages 9498 - 502, XP002954392
- KIM, E. K. ET AL.: "Expression of FAS within hypothalamic neurons: a model for decreased food intake after C75 treatment", *AM JPHYSIOL ENDOCRINOL METAB*, vol. 283, 2002, pages E867 - 79
- CLEGG, D. J. ET AL.: "Comparison of central and peripheral administration of C75 on food intake, body weight, and conditioned taste aversion", *DIABETES*, vol. 51, 2002, pages 3196 - 201, XP002422150, DOI: doi:10.2337/diabetes.51.11.3196
- GAO, S.; LANE, M. D.: "Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem", *PROC NATL ACAD SCI USA*, vol. 100, 2003, pages 5628 - 33, XP002422151, DOI: doi:10.1073/pnas.1031698100
- WORTMAN, M. D. ET AL.: "C75 inhibits food intake by increasing CNS glucose metabolism", *NAT MED*, vol. 9, 2003, pages 483 - 5, XP002422152, DOI: doi:10.1038/nm0503-483
- TAKAHASHI, K. A. ET AL.: "The anorexigenic fatty acid synthase inhibitor, C75, is a nonspecific neuronal activator", *ENDOCRINOLOGY*, vol. 145, 2004, pages 184 - 93
- HU, Z. ET AL.: "Hypothalamic malonyl-CoA as a mediator of feeding behavior", *PROC NATL ACAD SCI USA*, vol. 100, 2003, pages 12624 - 9, XP002422153, DOI: doi:10.1073/pnas.1834402100
- LANDREE, L. E. ET AL.: "C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism", *J BIOL CHEM*, vol. 279, 2004, pages 3817 - 27, XP002312245
- THUPARI, J. N. ET AL.: "Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass", *AM J PHYSIOL ENDOCRINOL METAB*, vol. 287, 2004, pages E97 - E104
- KIM, E. K. ET AL.: "C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase", *JBiol CHEM*, vol. 279, 2004, pages 19970 - 6, XP001204527, DOI: doi:10.1074/jbc.M402165200
- CHA, S. H. ET AL.: "Long-term effects of a fatty acid synthase inhibitor on obese mice: food intake, hypothalamic neuropeptides, and UCP3", *BIOCHEM BIOPHYS RES COMMUN*, vol. 317, 2004, pages 301 - 8, XP004500211, DOI: doi:10.1016/j.bbrc.2004.03.026
- MILLER, I. ET AL.: "Anorexigenic C75 alters c-Fos in mouse hypothalamic and hindbrain subnuclei", *NEUROREPORT*, vol. 15, 2004, pages 925 - 9
- LIU, L. H. ET AL.: "Effects of a fatty acid synthase inhibitor on adipocyte differentiation of mouse 3T3-L1 cells", *ACTA PHARMACOL SIN*, vol. 25, 2004, pages 1052 - 7
- YANG, N. ET AL.: "C75 [4-methylene-2-octyl-5-oxo-tetrahydro-furan-3-carboxylic acid] activates carnitine palmitoyltransferase- in isolated mitochondria and intact cells without displacement of bound malonyl CoA", *J PHARMACOL EXP THER*, vol. 312, 2005, pages 127 - 33
- TU, Y. ET AL.: "C75 alters central and peripheral gene expression to reduce food intake and increase energy expenditure", *ENDOCRINOLOGY*, vol. 146, 2005, pages 486 - 93
- NICOT, C. ET AL.: "C75 activates malonyl-CoA sensitive and insensitive components of the CPT system", *BIOCHEM BIOPHYS RES COMMUN*, vol. 325, 2004, pages 660 - 4, XP004635474, DOI: doi:10.1016/j.bbrc.2004.10.085
- LEONHARDT, M.; LANGHANS, W.: "Fatty acid oxidation and control of food intake", *PHYSIOL BEHAV*, vol. 83, 2004, pages 645 - 51, XP004696963, DOI: doi:10.1016/j.physbeh.2004.07.033
- SCHMID, B. ET AL.: "Inhibition of fatty acid synthase prevents preadipocyte differentiation", *BIOCHEM BIOPHYS RES COMMUN*, vol. 328, 2005, pages 1073 - 82, XP004747580, DOI: doi:10.1016/j.bbrc.2005.01.067
- HU, Z. ET AL.: "Effect of centrally administered C75, a fatty acid synthase inhibitor, on ghrelin secretion and its downstream effects", *PROC NATL ACAD SCI U S A*, vol. 102, no. 3, 2005, pages 972 - 7
- MCCULLOUGH, L. D. ET AL.: "Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke", *JBiol CHEM*, vol. 280, 2005, pages 20493 - 502
- KUHAJDA, F. P. ET AL.: "The connections between C75 and obesity drug-target pathways", *TRENDS PHARMACOL SCI*, vol. 26, 2005, pages 541 - 4, XP005129118, DOI: doi:10.1016/j.tips.2005.09.002
- RONNETT, G. V. ET AL.: "Fatty acid metabolism as a target for obesity treatment", *PHYSIOL BEHAV*, vol. 85, 2005, pages 25 - 35, XP005000907, DOI: doi:10.1016/j.physbeh.2005.04.014
- BENTEBIBEL, A. ET AL.: "Novel effect of C75 on carnitine palmitoyltransferase I activity and palmitate oxidation", *BIOCHEMISTRY*, vol. 45, 2006, pages 4339 - 50
- DRIDI, S. ET AL.: "FAS inhibitor cerulein reduces food intake and melanocortin receptor gene expression without modulating the other (an)orexigenic neuropeptides in chickens", *AM J PHYSIOL REGUL INTEGR COMP PHYSIOL*, vol. 291, 2006, pages R138 - 47
- HU, Z. ET AL.: "A role for hypothalamic malonyl-CoA in the control of food intake", *J Biol CHEM*, vol. 280, 2005, pages 39681 - 3
- OBICI, S. ET AL.: "Central administration of oleic acid inhibits glucose production and food intake", *DIABETES*, vol. 51, 2002, pages 271 - 5
- LANDREE, L. E. ET AL.: "C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism", *JBiol CHEM*, vol. 279, 2004, pages 3817 - 27, XP002312245
- "Cancer Principles and Practice of Oncology", 15 February 2001, LIPPINCOTT WILLIAMS & WILKINS PUBLISHERS
- MILLER, T.A. ET AL., *J. MED. CHEM.*, vol. 46, no. 24, 2003, pages 5097 - 5116
- 87; M. YALPANI: "Cholesterol Lowering Drugs", *CHEMISTRY & INDUSTRY*, 5 February 1996 (1996-02-05), pages 85 - 89, XP001525979
- EUROPEAN J OF CANCER, vol. 35, no. 9, 1999, pages 1394 - 1401
- PNAS, vol. 89, 1992, pages 7384
- JNCI, vol. 69, 1982, pages 475
- ARCH. OPHTHALMOL., vol. 108, 1990, pages 573
- ANAT. REC., vol. 238, 1994, pages 68
- FEBS LETTERS, vol. 372, 1995, pages 83
- CLIN. ORTHOP., vol. 313, 1995, pages 76
- J. MOL. ENDOCRINOL., vol. 16, 1996, pages 107
- JPN. J. PHARMACOL., vol. 75, 1997, pages 105
- CANCER RES., vol. 57, 1997, pages 1625
- CELL, vol. 93, 1998, pages 705
- INTL. J. MOL. MED., vol. 2, 1998, pages 715
- J. BIOL. CHEM., vol. 274, 1999, pages 9116
- FERNANDEZ ET AL., *J. LAB. CLIN. MED.*, vol. 105, 1985, pages 141 - 145
- NATURE BIOTECHNOLOGY, vol. 17, October 1999 (1999-10-01), pages 963 - 968
- KIM ET AL., *NATURE*, vol. 362, 1993, pages 841 - 844
- CLIN. CHEM. LA. MED., vol. 38, 2000, pages 679 - 692
- THROMB. HAEMOST., vol. 80, 1998, pages 10 - 23
- THROMBOSIS RES., vol. 101, 2001, pages 329 - 354
- BUME-JENSEN; HUNTER, *NATURE*, vol. 411, 2001, pages 355 - 365



- E.S. FORD ET AL.: "Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP-III)", JAMA, vol. 287, no. 3, 16 January 2002 (2002-01-16), pages 356 - 359
- KIEC-KONONOWICZ, K. ET AL., PHARMAZIE, vol. 55, 2000, pages 349 - 55
- LAZEWSKA, D. ET AL., PHARMAZIE, vol. 56, 2001, pages 927 - 32
- SASSE, A. ET AL., ARCH. PHARM.(WEINHEIM, vol. 334, 2001, pages 45 - 52
- REIDEMEISTER, S. ET AL., PHARMAZIE, vol. 55, 2000, pages 83 - 6
- SASSE, A. ET AL., J. MED. CHEM., vol. 43, 2000, pages 3335 - 43
- PEPT. SCI., vol. 8, no. 8, August 2002 (2002-08-01), pages 461 - 75
- DEL MAR-GRASA, M. ET AL., OBESITY RESEARCH, vol. 9, 2001, pages 202 - 9
- OLITVAK, D.A. ET AL., DIG. DIS. SCI., vol. 44, no. 3, 1999, pages 643 - 48
- BATTERHAM ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 88, 2003, pages 3989 - 3992
- "Patent focus on new anti-obesity agents", EXP. OPIN. THER. PATENTS, vol. 10, 2000, pages 819 - 831
- "Novel anti-obesity drugs", EXP. OPIN. INVEST. DRUGS, vol. 9, 2000, pages 1317 - 1326
- "Recent advances in feeding suppressing agents: potential therapeutic strategy for the treatment of obesity", EXP. OPIN. THER. PATENTS, vol. 11, 2001, pages 1677 - 1692
- EXP. OPIN. INVEST. DRUGS, vol. 9, 2000, pages 1327 - 1346
- EXP. OPIN. INVEST. DRUGS, vol. 9, 2000, pages 1553 - 1571
- SHIRLING; GOTTLIEB, INT. J. SYST. BACTERIOL., vol. 16, 1966, pages 313 - 340
- A. KORNERUP; J.H. WAUSCHER: "Methuen Handbook of Colour", 1978
- JAYAKUMAR A; TAI MH; HUANG WY; AL-FEEL W; HSU M; ABU-ELHEIGA L; CHIRALA SS; WAKIL SJ: "Human fatty acid synthase: properties and molecular cloning", PROC NATL ACAD SCI U S A., vol. 92, no. 19, 12 September 1995 (1995-09-12), pages 8695 - 9, XP002195434, DOI: doi:10.1073/pnas.92.19.8695
- THOMPSON BJ; STERN A; SMITH S: "Purification and properties of fatty acid synthetase from a human breast cell line", BIOCHIM BIOPHYS ACTA, vol. 662, no. 1, 13 November 1981 (1981-11-13), pages 125 - 30, XP023514651, DOI: doi:10.1016/0005-2744(81)90232-1
- LINN TC: "Purification and crystallization of rat liver fatty acid synthetase", ARCH BIOCHEM BIOPHYS, vol. 209, no. 2, July 1981 (1981-07-01), pages 613 - 9, XP024804633, DOI: doi:10.1016/0003-9861(81)90320-9
- JIANG G; LI Z; LIU F; ELLSWORTH K; DALLAS-YANG Q; WU M; RONAN J; ESSAU C; MURPHY C; SZALKOWSKI D: "Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearyl-CoA desaturase-1", J. CLIN. INVEST., vol. 115, 2003, pages 1030 - 1038, XP008137869, DOI: doi:10.1172/JCI200523962
- JIANG G; LI Z; LIU F; ELLSWORTH K; DALLAS-YANG Q; WU M; RONAN J; ESSAU C; MURPHY C; SZALKOWSKI D: "Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearyl-CoA desaturase-1", J. CLIN. INVEST., vol. 115, 2003, pages 1030 - 1038
- MANNAERTS GP; DEBEER LJ; THOMAS J; DESCHPEPPER PJ: "Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats", J. BIOL. CHEM., vol. 254, 1979, pages 4585 - 4595
- WANG ET AL., NATURE, vol. 441, 2006, pages 358

#### Citation (search report)

- [Y] WO 2005115400 A2 20051208 - MERCK & CO INC [US], et al
- [A] WO 2005117590 A2 20051215 - FASGEN LLC [US], et al
- [A] US 5981575 A 19991109 - KUHAJDA FRANCIS P [US], et al
- [Y] WANG JUN ET AL: "Platensimycin is a selective FabF inhibitor with potent antibiotic properties", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 441, 18 May 2006 (2006-05-18), pages 358 - 361, XP002443080, ISSN: 0028-0836, DOI: 10.1038/NATURE04784
- [Y] CAI SUI XIONG ET AL: "A chemical genetics approach for the discovery of apoptosis inducers: from phenotypic cell based HTS assay and structure-activity relationship studies, to identification of potential anticancer agents and molecular targets.", CURRENT MEDICINAL CHEMISTRY 2006 LNKD- PUBMED:17017915, vol. 13, no. 22, 1 September 2006 (2006-09-01), pages 2627 - 2644, XP002685226, ISSN: 0929-8673
- [A] RONNETT G V ET AL: "Fatty acid metabolism as a target for obesity treatment", PHYSIOLOGY AND BEHAVIOR, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 85, no. 1, 19 May 2005 (2005-05-19), pages 25 - 35, XP027726339, ISSN: 0031-9384, [retrieved on 20050519]
- [A] HIRSCH JULES: "The search for new ways to treat obesity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 14, 9 July 2002 (2002-07-09), pages 9096 - 9097, XP002685227, ISSN: 0027-8424

#### Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

#### DOCDB simple family (publication)

**WO 2008039327 A2 20080403; WO 2008039327 A3 20080508;** AU 2007300627 A1 20080403; AU 2007300627 B2 20120216; CA 2664113 A1 20080403; CA 2664113 C 20130528; CA 2770486 A1 20080403; CA 2770486 C 20140715; EP 2083831 A2 20090805; EP 2083831 A4 20121219; EP 2083831 B1 20131225; EP 2698157 A1 20140219; EP 2698157 B1 20150520; EP 2946778 A1 20151125; JP 2010504329 A 20100212; JP 5489333 B2 20140514; US 2010022630 A1 20100128; US 2012190747 A1 20120726; US 8173629 B2 20120508; US 8598153 B2 20131203

#### DOCDB simple family (application)

**US 2007020226 W 20070918;** AU 2007300627 A 20070918; CA 2664113 A 20070918; CA 2770486 A 20070918; EP 07838438 A 20070918; EP 13188869 A 20070918; EP 15166422 A 20070918; JP 2009529213 A 20070918; US 201213435130 A 20120330; US 31100507 A 20070918